# US 2010/0168221 A1 · Pharmaceutical composition for treating hepatitis b virus and health food product having hepatitis b virus inhibiting effects > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2010/0168221 A1 - Document ID: US20100168221A1 - Status: Published application - Kind: A1 - Application number: 12/648,986 - Filed: 2009-12-29 - Published: 2010-07-01 - Earliest claimed: 2008-12-31 - Assignees: Industrial Technology Research Institute - Inventors: Lain-Tze LEE; Shau-Feng Chang; Chia-Yu Lin; Hui-Yen Wu; Shu-Feng Chen; Jinun-Ban Yeh - Web page: https://patentgrep.com/patent/US20100168221A1 ## CPC - A61K 36/45: Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry - A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin - A61K 36/15: Pinaceae (Pine family), e.g. pine or cedar - A61K 36/185: Magnoliopsida (dicotyledons) - A61K 36/73: Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn - A61K 36/87: Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine - A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics - A61P 31/12: Antivirals - A61P 31/20: for DNA viruses - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention provides a pharmaceutical composition for treating hepatitis B, including: an effective amount of proanthocyanidins; and a pharmaceutically acceptable carrier or salt, wherein a formula of the monomer of the proanthocyanidins is shown in the following: , wherein R1 is OCH3, R2 is OH and R3 is H, or R1 is OH and R2 and R3 both are H, or R1 and R2 both are OH and R3 is H, or R1, R2 and R3 all are OH, and R4 is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar or 3-(β)-O-sugar. Bonding between adjacent monomers take place at C4, C8 Carbon-carbon bond or C2, C7 oxygen bond of A type or C4, C8 or C4, C6 Carbon-carbon bond of B type or C type of proanthocyanidins. And the polymerized number is from 2 to 30. ## Claims ### Claim 1 A pharmaceutical composition for treating hepatitis B, comprising: an effective amount of proanthocyanidins wherein a formula of a monomer of the proanthocyanidins is shown in the following: wherein R1 is OCH3, R2 is OH and R3 is H, or R1 is OH and R2 and R3 both are H, or R1 and R2 both are OH and R3 is H, or R1, R2 and R3 all are OH, and R4 is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar or 3-(β)-O-sugar; and a pharmaceutically acceptable carrier or salt. ### Claim 2 (depends on 1) The pharmaceutical composition for treating hepatitis B as claimed in claim 1, wherein a bonding between adjacent monomers of the proanthocyanidins take place at C4, C8 carbon-carbon bond, C4, C6 carbon-carbon bond or C2, C7 oxygen bond. ### Claim 3 (depends on 1) The pharmaceutical composition for treating hepatitis B as claimed in claim 1, wherein a polymerized number of the proanthocyanidins is about 2-30. ### Claim 4 (depends on 1) The pharmaceutical composition for treating hepatitis B as claimed in claim 1, wherein the monomer comprises (R) or (S) optical isomers at C4. ### Claim 5 (depends on 1) The pharmaceutical composition for treating hepatitis B as claimed in claim 1, wherein the monomer of the proanthocyanidins comprises a flavonoid. ### Claim 6 (depends on 5) The pharmaceutical composition for treating hepatitis B as claimed in claim 5, wherein the flavonoid comprises catechin, epicatechin, epiafzetechin, gallocatechin, galloepicatechin, epigallocatechin, gallates, flavonols, flavandiols, leucocyanidins or procynidins. ### Claim 7 (depends on 1) The pharmaceutical composition for treating hepatitis B as claimed in claim 1, wherein the monomer of the proanthocyanidins comprises a flavan-3-ol. ### Claim 8 (depends on 1) The pharmaceutical composition for treating hepatitis B as claimed in claim 1, wherein the proanthocyanidins is extracted from a plant. ### Claim 9 (depends on 8) The pharmaceutical composition for treating hepatitis B as claimed in claim 8, wherein the plant comprises a plant belonging to the Ericaceae, Rosaceae, Pinaceae, Vitaceae or Urticaceae family. ### Claim 10 (depends on 9) The pharmaceutical composition for treating hepatitis B as claimed in claim 9, wherein the plant belonging to the Urticaceae family comprises Boehmeria nivea (L.) Gaud. ### Claim 11 (depends on 8) The pharmaceutical composition for treating hepatitis B as claimed in claim 8, wherein the plant comprises Boehmeria nivea (L.) Gaud. ### Claim 12 A health food product having hepatitis B virus inhibiting effects, comprising: an effective amount of proanthocyanidins wherein a formula of a monomer of the proanthocyanidins is shown in the following: wherein R1 is OCH3, R2 is OH and R3 is H, or R1 is OH and R2 and R3 both are H, or R1 and R2 both are OH and R3 is H, or R1, R2 and R3 all are OH, and R4 is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar or 3-(β)-O-sugar. ### Claim 13 (depends on 12) The health food product having hepatitis B virus inhibiting effects as claimed in claim 12, wherein a bonding between adjacent monomers of the proanthocyanidins take place at C4, C8 carbon-carbon bond, C4, C6 carbon-carbon bond or C2, C7 oxygen bond. ### Claim 14 (depends on 12) The health food product having hepatitis B virus inhibiting effects as claimed in claim 12, wherein a polymerized number of the proanthocyanidins is about 2-30. ### Claim 15 (depends on 12) The health food product having hepatitis B virus inhibiting effects as claimed in claim 12, wherein the monomer comprises (R) or (S) optical isomers at C4. ### Claim 16 (depends on 12) The health food product having hepatitis B virus inhibiting effects as claimed in claim 12, wherein the monomer of the proanthocyanidins comprises a flavonoid. ### Claim 17 (depends on 16) The health food product having hepatitis B virus inhibiting effects as claimed in claim 16, wherein the flavonoid comprises catechin, epicatechin, epiafzetechin, gallocatechin, galloepicatechin, epigallocatechin, gallates, flavonols, flavandiols, leucocyanidins or procynidins. ### Claim 18 (depends on 12) The health food product having hepatitis B virus inhibiting effects as claimed in claim 12, wherein the monomer of the proanthocyanidins comprises a flavan-3-ol. ### Claim 19 (depends on 12) The health food product having hepatitis B virus inhibiting effects as claimed in claim 12, wherein the proanthocyanidins is extracted from a plant. ### Claim 20 (depends on 19) The health food product having hepatitis B virus inhibiting effects as claimed in claim 19, wherein the plant comprises a plant belonging to the Ericaceae, Rosaceae, Pinaceae, Vitaceae or Urticaceae family. ### Claim 21 (depends on 20) The health food product having hepatitis B virus inhibiting effects as claimed in claim 20, wherein the plant belonging to the Urticaceae family comprises Boehmeria nivea (L.) Gaud. ### Claim 22 (depends on 19) The health food product having hepatitis B virus inhibiting effects as claimed in claim 19, wherein the plant comprises Boehmeria nivea (L.) Gaud.